Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S536 get pertinent baseline variables to be able to correlate with outcomes. Main Outcome Measures: The primary endpoint was to evaluate quality of life measures including medical, psychological, and social parameters. Results: Between 2010 and 2018, 362 adult patients underwent HSCT, of them, 148 had relapsed disease or died, 52 lost to follow-up, 42 declined to participate. A total of 120 survivors participated in the study with a median age of 49 years (range: 2273). The median follow-up time was 75 months (range: 38-147 months). 66 (55%) patients were males, 79 (66%) had autoHSCT and 41 (34%) had alloHSCT. Twenty-four (20%) patients were diagnosed with leukemia, 61 (51%) with lymphoma, 23 (19%) with myeloma, and 12 (10%) had other diseases. Sixty (50%) patients received maintenance treatment post-transplant. Recurrent pain, nausea and chronic fatigue were reported by 49 (41%), 21 (18%), and 44 (37%) patients. Newly occurring medical illnesses post-transplant included recurrent infections (17%), ocular (31%), dental (38%), respiratory (20%), cardiac (13%), endocrine (20%), secondary cancers (29%), infertility (82%), memory problems (30%). Despite that, 97 (80%) survivors reported being close to their partners, 78 (65%) still interested in sexual relationships, 108 (90%) and 98 (82%) have a strong support from family and friends respectively, 80 (66%) returned to work, and 93 (77%) are satisfied with their quality of life. Conclusions: Long-term survivors after HSCT were capable of creating coping strategies in terms of social and mental health despite many medical illnesses. Keywords: CT, survivors, hematopoietic cell transplantation, social life, mental health, long-term complications CT-629 The Impact of Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes in Patients Diagnosed With Acute Myeloid Leukemia and Persistent Measurable Residual Disease: A Retrospective Cohort Racha Khodor MD, Ammar Zahreddine RN, Maya Charafeddine BS, Nour Moukalled MD, Jean El Cheikh MD, Ali Bazarbachi MD, PhD, Iman Abou Dalle MD American University of Beirut, Beirut, Lebanon Context: Despite achieving complete remission with standard chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), patients with acute myeloid leukemia (AML) are still at high risk of disease relapse. Maintenance therapy post alloHSCT, including hypomethylating agents or FLT3 inhibitors, is implemented in our institutional guidelines to mitigate this risk. Moreover, measurable residual disease (MRD) status of patients is considered an important independent prognostic marker associated with poorer long-term outcomes. Objective: The aim of this research is to evaluate the impact of maintenance therapy post allo-HSCT on the survival outcomes of transplanted patients based on their pre-transplant MRD status. Design: We performed a retrospective chart review for a total of 108 adult patients diagnosed with AML and who had undergone allo-HSCT at our center between 2015 and 2021. Main Outcome Measures: We estimated both overall survival (OS) and relapsed free survival (RFS) using Kaplan Meier curves from the time of transplant among patients who received maintenance treatment based on their MRD status pre-transplant. MRD status was determined using multiparametric flow cytometry, next-generation sequencing, and/or RT-PCR. Results: The median age at transplant was 47 years, 60% (n=65) of the patients were males. 66.7% of patients had an intermediate ELN risk. Among the 108 patients, 77 received maintenance therapy post-transplant, of which 36 patients had a detectable pre-transplant MRD and 41 patients did not. Maintenance therapy consisted mainly of low dose hypomethylating agent (HMA) azacitidine in 68.8% (n=53) of the patients, followed by tyrosine kinase inhibitors (TKI) in 18.2% (n=14) of the patients, and a combination of HMA with TKI, and/ or a BCL2 inhibitor in 13% (n=10). Median duration of maintenance was 20.7 months (range: 0.1-84.2 months). Among patients who received maintenance therapy (n=77), there was no statistically significant difference in both OS and RFS based on MRD status pre-transplant, (4-year OS: 76% versus 63%, P=0.6; 4-year RFS: 63% versus 57%, P=0.53). Conclusions: Our analysis showed no significant difference in survival outcomes of patients receiving maintenance therapy post allo-HSCT based on their pre-transplant MRD. Maintenance treatment could overcome the negative predictive value of detectable MRD to be confirmed by larger prospective studies. Keywords: CT, acute myeloid leukemia, allogeneic stem cell transplantation, maintenance, hypomethylating agents, FLT3 inhibitors, measurable residual disease CT-630 Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM) Sireesha Asoori MBBS, MSPH, Thomas Martin MD, Jeffrey Wolf MD, Alfred Chung MD, Shagun Arora MD University of California, San Francisco, San Francisco, USA Introduction: Teclistamab is a bispecific BCMA-CD3 directed T-cell antibody (BsAb) recently approved as monotherapy against RRMM. In the MajesTEC-1 study, infections were seen in 76.4% of the patients and 44.8% of them were Grade 3 or greater. Methods: We performed a single-center retrospective study of patients treated with teclistamab at UCSF and data was collected until May 23, 2023. Results: 37 patients received commercial teclistamab and were included in the analysis. Median age was 71 (range 50-89 years), 54% were female, 52% Caucasian, 21% Asian and 16% Hispanic. Infections were common and occurred in 27/37 (72.97%) of the patients; 8 patients (21.6%) had >1 infection. Majority of the infections were CMV reactivations (n=18), as serial CMV monitoring by PCR was performed in 28 asymptomatic patients. The median peak value was 2721 IU/ml (range: 70-77655), and antiviral treatment was initiated in only 3 patients. No organ infection occurred and viremia resolved spontaneously in most. Overall, 12/27 (44.5%) patients required antimicrobial treatment, and 5 (18.51%) required re-hospitalization. There were 7 bacterial infections; 3 E.
RkJQdWJsaXNoZXIy MTk3NTQxMg==